{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vehicle+%28TID%29",
    "query": {
      "intervention": "Vehicle (TID)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 46,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vehicle+%28TID%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-09T01:55:26.869Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05133180",
      "title": "Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dry Eye"
      ],
      "interventions": [
        {
          "name": "Oxervate",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Dompé Farmaceutici S.p.A",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 104,
      "start_date": "2022-01-19",
      "completion_date": "2022-12-19",
      "has_results": true,
      "last_update_posted_date": "2024-06-07",
      "last_synced_at": "2026-09-09T01:55:26.869Z",
      "location_count": 7,
      "location_summary": "Glendale, California • Newport Beach, California • Baltimore, Maryland + 4 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Houston",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05133180"
    },
    {
      "nct_id": "NCT00006994",
      "title": "S9908: Glutamine in Treating Mucositis Caused by Radiation Therapy in Patients With Newly Diagnosed Cancer of the Mouth or Throat",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cancer-related Problem/Condition",
        "Head and Neck Cancer",
        "Pain"
      ],
      "interventions": [
        {
          "name": "glutamine",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "l-glutamine placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 23,
      "start_date": "2001-11",
      "completion_date": "2006-04",
      "has_results": false,
      "last_update_posted_date": "2015-11-18",
      "last_synced_at": "2026-09-09T01:55:26.869Z",
      "location_count": 106,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 68 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006994"
    },
    {
      "nct_id": "NCT00713349",
      "title": "Controlled Study of the Effect of Xenaderm® Ointment Vehicle Versus White Petrolatum on Healing",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Wounds"
      ],
      "interventions": [
        {
          "name": "Xenaderm Vehicle",
          "type": "DRUG"
        },
        {
          "name": "Placebo comparator",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Healthpoint",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2008-06",
      "completion_date": "2008-09",
      "has_results": true,
      "last_update_posted_date": "2013-12-06",
      "last_synced_at": "2026-09-09T01:55:26.869Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00713349"
    },
    {
      "nct_id": "NCT02165605",
      "title": "HylaCare in the Treatment of Acute Skin Changes in Patients Undergoing Radiotherapy for Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "HylaCare",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 99 Years · Female only"
      },
      "enrollment_count": 28,
      "start_date": "2012-08",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2020-10-22",
      "last_synced_at": "2026-09-09T01:55:26.869Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02165605"
    },
    {
      "nct_id": "NCT01913106",
      "title": "HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Prostatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "HSV-tk +Valacyclovir in Combination with Brachytherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Methodist Hospital Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 25,
      "start_date": "2007-06",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2016-07-01",
      "last_synced_at": "2026-09-09T01:55:26.869Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01913106"
    },
    {
      "nct_id": "NCT05454956",
      "title": "Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Meibomian Gland Dysfunction",
        "Blepharitis",
        "Demodex Infestation"
      ],
      "interventions": [
        {
          "name": "TP-03",
          "type": "DRUG"
        },
        {
          "name": "TP-03 Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tarsus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2022-08-03",
      "completion_date": "2023-05-18",
      "has_results": true,
      "last_update_posted_date": "2025-10-01",
      "last_synced_at": "2026-09-09T01:55:26.869Z",
      "location_count": 5,
      "location_summary": "Northridge, California • Kansas City, Missouri • Cary, North Carolina + 2 more",
      "locations": [
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Cary",
          "state": "North Carolina"
        },
        {
          "city": "Shelby",
          "state": "North Carolina"
        },
        {
          "city": "New Freedom",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05454956"
    },
    {
      "nct_id": "NCT00651612",
      "title": "Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Concurrent brimonidine 0.2% and 0.5% timolol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 604,
      "start_date": "2005-11",
      "completion_date": "2007-01",
      "has_results": false,
      "last_update_posted_date": "2008-04-03",
      "last_synced_at": "2026-09-09T01:55:26.869Z",
      "location_count": 1,
      "location_summary": "Newport Beach, California",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00651612"
    },
    {
      "nct_id": "NCT00695565",
      "title": "Efficacy and Safety Study of ARC-4558 for Management of Pain Associated With Painful Diabetic Neuropathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Painful Diabetic Neuropathy"
      ],
      "interventions": [
        {
          "name": "Placebo Gel",
          "type": "DRUG"
        },
        {
          "name": "Clonidine Topical Gel (ARC-4558)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arcion Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 180,
      "start_date": "2008-05",
      "completion_date": "2010-02",
      "has_results": true,
      "last_update_posted_date": "2016-11-08",
      "last_synced_at": "2026-09-09T01:55:26.869Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • Sacramento, California • Santa Monica, California + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00695565"
    },
    {
      "nct_id": "NCT00939276",
      "title": "Macular Edema Incidence/Severity Reduction With Nevanac",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "Nepafenac ophthalmic suspension, 0.1% (NEVANAC®)",
          "type": "DRUG"
        },
        {
          "name": "Nepafenac ophthalmic suspension vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 175,
      "start_date": "2009-08",
      "completion_date": "2011-08",
      "has_results": false,
      "last_update_posted_date": "2012-10-23",
      "last_synced_at": "2026-09-09T01:55:26.869Z",
      "location_count": 1,
      "location_summary": "Fort Worth, Texas",
      "locations": [
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00939276"
    },
    {
      "nct_id": "NCT03142178",
      "title": "3VM for Treatment of Chronic Osteoarthritis Knee Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Arthritis, Degenerative"
      ],
      "interventions": [
        {
          "name": "Experimental: 3VM1001 active 2g Cream 3 times daily",
          "type": "DRUG"
        },
        {
          "name": "Experimental: 3VM1001 active 3g Cream 3 times daily",
          "type": "DRUG"
        },
        {
          "name": "Experimental: 3VM1001 active 3g Cream 4 times daily",
          "type": "DRUG"
        },
        {
          "name": "Placebo: 3VM1001 vehicle 2g Cream 3 times daily",
          "type": "DRUG"
        },
        {
          "name": "Placebo: 3VM1001 vehicle 3g Cream 3 times daily",
          "type": "DRUG"
        },
        {
          "name": "Placebo: 3VM1001 vehicle 3g Cream 4 times daily",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CDA Research Group, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2017-04-30",
      "completion_date": "2018-06-01",
      "has_results": false,
      "last_update_posted_date": "2018-07-06",
      "last_synced_at": "2026-09-09T01:55:26.869Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03142178"
    }
  ]
}